Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study
The pathogenesis of ARDS appears to be from damage to the alveolar-capillary barrier, which is composed of the microvascular endothelium and the alveolar epithelium. This damage may occur from direct or indirect lung injury. The mechanism of injury to the alveolar capillary barrier appears to be through neutrophil-mediated injury, pro-inflammatory cytokines, ventilator-induced lung injury with alveolar over distention and abnormalities of the coagulation system. This results in blood clot formation in the microcirculation of the lung. Thrombolytics can dissolve blood clots and result in increased blood flow to the organs. This treatment may benefit ARDS patients, thus the purpose of this study.
Hardaway, et al.studied the effects of thrombolytics on ARDS in pigs. The experimental group showed improved oxygenation and survival as compared to controls. There was no bleeding complications noted with this therapy. Dr. Hardaway followed this animal study with a phase I clinical trial involving 20 patients with ARDS. The patients were treated with IV streptokinase or urokinase. Nineteen of the 20 patients showed an increase in PA02 after thrombolytic therapy. There were no significant bleeding complications in patients that were critically ill on ventilators.
We propose an additional phase I pilot study to evaluate the effectiveness and safety of Tenecteplase for the treatment of ARDS. Unlike the other fibrinolytics studied in this disease state, Tenecteplase, is more fibrin specific and has increased resistance to plasminogen activator inhibitor (PAI-I) at greater levels than other available fibrinolytics. We have chosen an experimental dose escalation trial design of tenecteplase that has demonstrated initial safety trends in a Phase I acute ischemic stroke trial. The initial dose is 0.1 mg/kg IV and will increase to 0.2 mg/kg, 0.3 mg/kg, with a final cohort of patients receiving 0.4 mg/kg. Drug administration will be a single dose bolus in each cohort. Advancement of dose will occur if safety is not in question in the previous cohort. We hope this will provide an acceptable benefit risk ratio as the mortality of ARDS is approximately 30 - 60%. All patients will be closely monitored for any change in clotting parameters and signs of bleeding. Tenecteplase will be administered via a peripheral IV as described in the package insert.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Treatment of Acute Respiratory Distress Syndrome With Tenecteplase: A Dose Escalation Pilot Study: Phase I|
- Survival to Discharge
- Safety Analysis of Bleeding Complications
- Improved Pa02/Fi02 ratio
- Improved cardiac profile
- Incidence of organ failure
- Decreased ventilator days
- Decreased ICU days
|Study Start Date:||February 2007|
|Study Completion Date:||December 2008|
|Primary Completion Date:||November 2008 (Final data collection date for primary outcome measure)|
- Treatment of acute respiratory distress syndrome with tenecteplase, a dose escalation pilot study: phase I
- The study sample size will be 20 patients. The 20 patients will be divided into 4 groups with 5 patients in each group or cohort. The first cohort will received 0.1mg/kg of tenecteplase as a bolus via peripheral IV as described by the package insert and will be closely monitored for safety and efficacy. If there are no adverse events associated with tenecteplase, the second cohort of patients will be enrolled and will receive 0.2 mg/kg of tenecteplase IV bolus. If there are no safety issues, we will proceed with the next cohort at 0.3 mg/kg with a final cohort of patients receiving 0.4 mg/kg of tenecteplase IV bolus. Advancement of dose will occur if safety is not in question in the previous cohort.
- Tenecteplase will be given as a bolus via peripheral IV as described by package insert.
- Treatment will be initiated after informed consent is obtained and only >12 hrs after any subcutaneous Heparin has been stopped and >12 hrs after placement of a pulmonary artery catheter, central line or arterial line. Only patients meeting criteria for ARDS (see inclusion criteria) will be considered for the study.
- Pretreatment assessment: We will obtain informed consent, demographic data, physical examination and medical history, vital signs, PT, PTT, INR, ABG, hemoglobin hematocrit, liver enzymes, cardiac enzymes, creatinine, fibrinogen, fibrin split products, platelets, urine pregnancy test, EKG, chest x-ray, cardiac profile from Swan-Ganz catheter and ventilator settings before treatment begins.
- Assessment during treatment: Blood samples will be taken every 6 hours for 24 hours and analyzes for PT, PTT, INR, fibrinogen, fibrin split products, platelets, hemoglobin, and hematocrit. Arterial blood gas samples will be taken at hour 1, 2, 3, and every six hours until 24 hours post-injection. Cardiac profile, vital signs and ventilator settings will be monitored at hour 1, 2, 3, and every six hours until 24 hours post-infusion. Adverse events will be monitored every hour for 24 hours.
- Follow-up assessment: 72 hours post treatment physical exam, vital signs, weight, adverse events, cardiac profile, ventilator settings, PT, PTT, INR, fibrinogen, fibrin split products, platelets, ABG, hemoglobin and hematocrit, liver enzymes, cardiac enzymes, creatinine, EKG and chest x-ray will be obtained. Thirty days post treatment physical exam, vital signs, weight, mortality, adverse events will be followed.
- Patients will be monitored for signs of clinical bleeding.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00431379
|United States, Georgia|
|Medical Center of Central GA|
|Macon, Georgia, United States, 31201|
|Principal Investigator:||Dennis W. Ashley, MD, FACS||Medical Center of Central GA|
|Study Chair:||Debra M Kitchens, RN, CEN||Medical Center of Central Georgia|